https://www.businesswire.com/news/home/20241205877164/en/Nuvig-Therapeutics-Announces-%24161-Million-Series-B-Financing-and-Progression-to-Phase-2-Development-with-Novel-Second-Generation-Immunomodulator

Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator (businesswire.com)